info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Rasagiline (Azilect)
502
Article source: Seagull Pharmacy
Nov 13, 2025

Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. Since its approval by the U.S. FDA in 2006, it has become an important treatment option for Parkinson's disease. Its precise indication positioning, standardized dosage form design, and standardized storage requirements constitute the core elements of clinical medication use.

Indications for Rasagiline (Azilect)

Core Therapeutic Area

Rasagiline is clearly indicated for the treatment of Parkinson's disease (PD), covering disease management across different stages from early to advanced.

The medication can be used as monotherapy or a key component of combination therapy regimens.

Clinical Application Scenarios

Monotherapy: For patients with early-stage Parkinson's disease who have not received levodopa treatment.

Combination therapy: Used as an adjunct to levodopa to improve motor fluctuation symptoms.

Special populations: Can be used in combination with other anti-Parkinsonian medications such as dopamine agonists.

Specifications and Properties of Rasagiline (Azilect)

0.5 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 0.5", and the other side is a smooth surface.

1 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 1", and the other side remains smooth.

Both dosage forms use the same excipient formula: mannitol, starch, pregelatinized starch, colloidal silicon dioxide, stearic acid, and talc, ensuring drug stability and bioavailability.

Storage Methods for Rasagiline (Azilect)

Temperature Control Standards

The medication should be stored at 25°C (77°F), with short-term fluctuations allowed within the range of 15°C to 30°C (59°F to 86°F).

Packaging and Environmental Requirements

Packaging specifications: Supplied in bottles containing 30 tablets.

Environmental protection: Avoid exposure to direct sunlight, humid environments, and contact with heat sources.

Safety Precautions

Immediately seal the bottle cap after each use.

Store in a safe location out of the reach of children.

Avoid storing together with strong oxidants, acids, or alkalis.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Rasagiline (Azilect)
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, and an important medication for the treatment of Parkinson's disease.How to Purchase Rasagiline (Az...
What Are the Side Effects of Resmetirom (Rezdiffra)?
Resmetirom (Rezdiffra) is the first thyroid hormone receptor-beta agonist approved by the U.S. FDA in 2024 through the accelerated approval pathway for the treatment of non-cirrhotic non-alcoholic ste...
Precautions for Using Resmetirom (Rezdiffra)
Resmetirom (Rezdiffra) is a thyroid hormone receptor-beta (THR-β) agonist and the first targeted drug approved for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to ...
How to Use Resmetirom (Rezdiffra)
Resmetirom (Rezdiffra) is a thyroid hormone receptor-beta agonist approved for marketing by the U.S. FDA in 2024. When used in combination with diet and exercise, this medication is indicated for the ...
How to Use Rasagiline (Azilect)
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, which was first approved for marketing in the United States in 2006. This medication is indicated for t...
Precautions for Using Rasagiline (Azilect)
Rasagiline (Azilect) is one of the important medications currently used for the treatment of Parkinson's disease. As a monoamine oxidase (MAO) inhibitor, this drug carries specific risks such as h...
What Are the Side Effects of Rasagiline (Azilect)?
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, approved for the treatment of Parkinson's disease. While this medication effectively improves motor...
How to Purchase Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is a next-generation kinase inhibitor and an important targeted medication for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK gene fusion-positive s...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved